Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj
Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj
– BEAT AML data highlight the potential for revumenib to advance the current standard of care –– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients –
– 第2阶段协议定义的R/R mNPM1 AML疗效人群的亚组分析（N=64）显示所有主要亚组均有反应，包括重度预处理患者 –
– 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort –
– 所有符合疗效可评估标准的入组患者在第2阶段R/R mNPM1 AML队列中CR+CRh为26%（20/77），ORR为48%（37/77） –
– 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML –
– 在BEAt AML试验中，探索revumenib与venetoclax/azacitidine联合使用在新诊断的mNPM1或KMT2Ar AML中的表现为100% ORR（37/37）和95% CRc（35/37） –
– BEAT AML data highlight the potential for revumenib to advance the current standard of care –
– BEAt AML数据突显了revumenib推动当前治疗标准的潜力 –
